Detalhe da pesquisa
1.
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Blood
; 143(8): 673-684, 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37883795
2.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood
; 2024 Apr 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38662991
3.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood
; 139(8): 1198-1207, 2022 02 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34469514
4.
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Blood
; 140(20): 2127-2141, 2022 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35709339
5.
Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study.
Eur J Neurol
; 31(3): e16174, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38085272
6.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood
; 138(10): 836-846, 2021 09 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34115103
7.
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood
; 135(25): 2266-2270, 2020 06 18.
Artigo
Inglês
| MEDLINE | ID: mdl-32244251
8.
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
N Engl J Med
; 378(13): 1211-1223, 2018 03 29.
Artigo
Inglês
| MEDLINE | ID: mdl-29590547
9.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 311-22, 2016 Jan 28.
Artigo
Inglês
| MEDLINE | ID: mdl-26639348
10.
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Blood
; 129(25): 3362-3370, 2017 06 22.
Artigo
Inglês
| MEDLINE | ID: mdl-28473407
11.
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Blood
; 127(25): 3215-24, 2016 06 23.
Artigo
Inglês
| MEDLINE | ID: mdl-27069256
12.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Lancet Oncol
; 18(2): 230-240, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28089635
13.
Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
Br J Haematol
; 197(4): 394-396, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35262916
14.
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blood
; 135(10): 773-777, 2020 03 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31951646
15.
Venous thromboembolism management practices and knowledge of guidelines: a survey of Australian haematologists and respiratory physicians.
Intern Med J
; 47(4): 436-446, 2017 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28150371
16.
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.
Intern Med J
; 52(7): 1286-1287, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35879233
17.
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care.
Cancers (Basel)
; 16(5)2024 Feb 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38473342
18.
A comparison of survey methods in studies of the nurse workforce.
Nurse Res
; 20(4): 22-7, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-23520709
19.
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
J Hematol Oncol
; 16(1): 72, 2023 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37422670
20.
Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis.
Leuk Lymphoma
; 64(13): 2057-2070, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37688482